CN102892765B - 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物 - Google Patents

具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物 Download PDF

Info

Publication number
CN102892765B
CN102892765B CN201180023678.6A CN201180023678A CN102892765B CN 102892765 B CN102892765 B CN 102892765B CN 201180023678 A CN201180023678 A CN 201180023678A CN 102892765 B CN102892765 B CN 102892765B
Authority
CN
China
Prior art keywords
amino
methyl
hydroxy
ethyl
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180023678.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102892765A (zh
Inventor
M·帕拉特坤诺斯
席微亚·芳奎那波
卡洛斯·普伊格杜兰
W·鲁默斯阿马多尔
荷西·艾瓜德博世
J·F·凯特厄拉加瓦罗耶斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall SA filed Critical Almirall SA
Publication of CN102892765A publication Critical patent/CN102892765A/zh
Application granted granted Critical
Publication of CN102892765B publication Critical patent/CN102892765B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201180023678.6A 2010-05-13 2011-05-13 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物 Expired - Fee Related CN102892765B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10382118A EP2386555A1 (en) 2010-05-13 2010-05-13 New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP10382118.7 2010-05-13
US36504510P 2010-07-16 2010-07-16
US61/365,045 2010-07-16
PCT/EP2011/002376 WO2011141180A1 (en) 2010-05-13 2011-05-13 NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

Publications (2)

Publication Number Publication Date
CN102892765A CN102892765A (zh) 2013-01-23
CN102892765B true CN102892765B (zh) 2015-04-29

Family

ID=42646365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180023678.6A Expired - Fee Related CN102892765B (zh) 2010-05-13 2011-05-13 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物

Country Status (38)

Country Link
US (1) US9643961B2 (enExample)
EP (2) EP2386555A1 (enExample)
JP (1) JP5851489B2 (enExample)
KR (1) KR101756497B1 (enExample)
CN (1) CN102892765B (enExample)
AR (1) AR081387A1 (enExample)
AU (1) AU2011252337C1 (enExample)
BR (1) BR112012026570A2 (enExample)
CA (1) CA2799099C (enExample)
CL (1) CL2012003171A1 (enExample)
CO (1) CO6592031A2 (enExample)
CR (1) CR20120574A (enExample)
CY (1) CY1118352T1 (enExample)
DK (1) DK2569308T3 (enExample)
EA (1) EA022358B1 (enExample)
EC (1) ECSP12012213A (enExample)
ES (1) ES2613355T3 (enExample)
GT (1) GT201200307A (enExample)
HR (1) HRP20170307T1 (enExample)
HU (1) HUE033244T2 (enExample)
IL (1) IL222538A (enExample)
LT (1) LT2569308T (enExample)
ME (1) ME02675B (enExample)
MX (1) MX2012012897A (enExample)
MY (1) MY171899A (enExample)
NZ (1) NZ602556A (enExample)
PE (1) PE20130215A1 (enExample)
PH (1) PH12012502237A1 (enExample)
PL (1) PL2569308T3 (enExample)
PT (1) PT2569308T (enExample)
RS (1) RS55725B1 (enExample)
SG (1) SG185007A1 (enExample)
SI (1) SI2569308T1 (enExample)
SM (2) SMT201700022T1 (enExample)
TW (1) TWI526442B (enExample)
UY (1) UY33362A (enExample)
WO (1) WO2011141180A1 (enExample)
ZA (1) ZA201207031B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2592077A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) * 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
WO2014083171A1 (en) 2012-11-30 2014-06-05 Harmonic Pharma Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TWI643853B (zh) * 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201440768A (zh) * 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CA2932486A1 (en) 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Benzhydryl derivatives for the treatment of respiratory diseases
WO2015082616A1 (en) * 2013-12-05 2015-06-11 Chiesi Farmaceutici S.P.A. Heteroaryl derivatives for the treatment of respiratory diseases
WO2015171753A1 (en) * 2014-05-06 2015-11-12 Visco Anthony G Methods of treating or preventing preterm labor
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
JP6903574B2 (ja) 2014-06-09 2021-07-14 バイオメトリー・インコーポレイテッドＢｉｏｍｅｔｒｙ Ｉｎｃ． 検体を測定するための低コストテストストリップ及び方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) * 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
EP4464772A3 (en) 2016-07-19 2024-12-04 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
CN113544121A (zh) * 2019-06-06 2021-10-22 中国医药研究开发中心有限公司 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
WO2022172296A1 (en) * 2021-02-12 2022-08-18 Gbr Laboratories Private Limited A process for preparing navafenterol and intermediates thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404481A (zh) * 2000-01-31 2003-03-19 辉瑞产品公司 用作pde4同功酶选择性抑制剂的烟酰胺苯并稠合的杂环衍生物
WO2008096127A2 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3370320D1 (en) 1983-09-26 1987-04-23 Magis Farmaceutici Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
EP1078629A3 (en) 1989-09-07 2001-05-23 Glaxo Group Limited Use of Salmeterol and salts for the treatment of inflammation and allergy
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
US5201308A (en) 1990-02-14 1993-04-13 Newhouse Michael T Powder inhaler
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
ES2113889T3 (es) 1990-09-26 1998-05-16 Pharmachemie Bv Dispositivos inhaladores provistos de un deposito para varias dosis de producto de inhalacion, dispositivo de transporte y camaras de turbulencia.
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
AU718263B2 (en) 1995-04-14 2000-04-13 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
CN1325129C (zh) 1995-06-21 2007-07-11 Meda制药有限及两合公司 带整体计量装置的药筒和药粉吸入器
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO1998009632A1 (en) 1996-09-06 1998-03-12 Merck & Co., Inc. Methods and compositions for treating preterm labor
JPH1171331A (ja) * 1997-08-27 1999-03-16 Tokyo Tanabe Co Ltd アミノシクロアルキルメタノール化合物
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
EP1204643B1 (en) 1999-08-20 2008-06-04 Dow AgroSciences LLC Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
KR100869721B1 (ko) 2000-12-28 2008-11-21 알미랄 에이쥐 신규한 퀴누클리딘 유도체 및 그를 함유한 의약 조성물
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2005263486B2 (en) 2004-07-16 2011-05-12 Astrazeneca Ab Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
EP1924553A1 (en) * 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
WO2007107828A2 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
AU2007303909A1 (en) 2006-10-04 2008-04-10 Pfizer Limited Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
CA2713322C (en) 2008-02-06 2017-01-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and their use in the treatment of pulmonary disorders
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
CN102405218B (zh) 2009-04-23 2014-06-04 施万制药 具蕈毒碱受体拮抗剂和β2 肾上腺素受体激动剂活性的二酰胺化合物
JP5379224B2 (ja) 2009-04-30 2013-12-25 帝人ファーマ株式会社 四級アンモニウム塩化合物
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
RS54365B1 (sr) 2011-06-10 2016-04-28 Chiesi Farmaceutici S.P.A. Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112014011351B1 (pt) 2011-11-11 2021-02-17 Gilead Apollo, Llc. inibidores de acc e usos dos mesmos
GEP201706656B (en) 2011-11-11 2017-04-25 Pfizer 2-thiopyrimidinones
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
HRP20180915T1 (hr) 2012-12-06 2018-07-27 Chiesi Farmaceutici S.P.A. Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
CN104854105B (zh) 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404481A (zh) * 2000-01-31 2003-03-19 辉瑞产品公司 用作pde4同功酶选择性抑制剂的烟酰胺苯并稠合的杂环衍生物
WO2008096127A2 (en) * 2007-02-07 2008-08-14 Argenta Discovery Ltd Bicyclo[2.2.1]hept-7-ylamine derivatives and their use as m3 muscarinic receptor modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Muscarinic antagonist-b-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review;Nicholas C Ray，等;《Expert Opin. Ther. Patents》;20090131;第19卷(第1期);第1-12页，尤其是第2页左栏第3段，图1-4 *

Also Published As

Publication number Publication date
ES2613355T3 (es) 2017-05-24
WO2011141180A8 (en) 2012-01-19
EP2386555A1 (en) 2011-11-16
PH12012502237A1 (en) 2013-02-04
PE20130215A1 (es) 2013-03-08
CA2799099C (en) 2018-03-13
US20160264557A1 (en) 2016-09-15
CR20120574A (es) 2012-11-26
CA2799099A1 (en) 2011-11-17
NZ602556A (en) 2013-10-25
AU2011252337A1 (en) 2012-12-20
EA022358B1 (ru) 2015-12-30
JP2013526494A (ja) 2013-06-24
GT201200307A (es) 2014-06-06
AU2011252337B2 (en) 2014-07-03
BR112012026570A2 (pt) 2017-12-19
WO2011141180A1 (en) 2011-11-17
ME02675B (me) 2017-06-20
PT2569308T (pt) 2017-02-24
SMT201700022T1 (it) 2017-03-08
IL222538A0 (en) 2012-12-31
CO6592031A2 (es) 2013-01-02
ZA201207031B (en) 2013-06-26
ECSP12012213A (es) 2012-11-30
IL222538A (en) 2015-11-30
AR081387A1 (es) 2012-08-29
EP2569308A1 (en) 2013-03-20
US9643961B2 (en) 2017-05-09
TWI526442B (zh) 2016-03-21
MX2012012897A (es) 2012-12-17
PL2569308T3 (pl) 2017-05-31
SMT201700022B (it) 2017-03-08
MY171899A (en) 2019-11-06
TW201139424A (en) 2011-11-16
KR20130062930A (ko) 2013-06-13
UY33362A (enExample) 2011-07-29
EA201201541A1 (ru) 2013-04-30
SG185007A1 (en) 2012-12-28
HUE033244T2 (hu) 2017-11-28
DK2569308T3 (da) 2017-02-20
CY1118352T1 (el) 2017-06-28
JP5851489B2 (ja) 2016-02-03
CL2012003171A1 (es) 2013-02-15
EP2569308B1 (en) 2016-11-23
KR101756497B1 (ko) 2017-07-10
SI2569308T1 (sl) 2017-02-28
CN102892765A (zh) 2013-01-23
HRP20170307T1 (hr) 2017-04-21
LT2569308T (lt) 2017-01-10
AU2011252337C1 (en) 2014-11-27
RS55725B1 (sr) 2017-07-31

Similar Documents

Publication Publication Date Title
CN102892765B (zh) 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物
CN103998443B (zh) 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂的活性的环己胺衍生物
CN101522631B (zh) 4-(2-氨基-1-羟基乙基)苯酚的衍生物作为β2肾上腺素能受体激动剂
CN104024245A (zh) 具有β2肾上腺素能激动剂和M3毒蕈碱拮抗剂活性的新型环己胺衍生物
US9315463B2 (en) Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
CN105142673B (zh) 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
CN101379057A (zh) 联苯基-2-基氨基甲酸1-[2-(2-氯-4-{[(r)-2-羟基-2-(8-羟基-2-氧代-1,2-二氢喹啉-5-基)乙基氨基]甲基}-5-甲氧基苯基氨甲酰基)乙基]哌啶-4-基酯的琥珀酸盐及其治疗肺疾病的用途
CN101939291A (zh) 作为β2肾上腺素能受体激动剂的4-(2-氨基-1-羟乙基)苯酚衍生物
HK1176929B (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
HK1176929A (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
NZ624784B2 (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
HK1197241B (en) New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150429